HRP20121078T1 - Farmaceutski sastav za lijeäśenje hiperaktivnog mjehura - Google Patents
Farmaceutski sastav za lijeäśenje hiperaktivnog mjehura Download PDFInfo
- Publication number
- HRP20121078T1 HRP20121078T1 HRP20121078AT HRP20121078T HRP20121078T1 HR P20121078 T1 HRP20121078 T1 HR P20121078T1 HR P20121078A T HRP20121078A T HR P20121078AT HR P20121078 T HRP20121078 T HR P20121078T HR P20121078 T1 HRP20121078 T1 HR P20121078T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- quinuclidin
- aminothiazol
- acetanilide
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 9
- 206010020853 Hypertonic bladder Diseases 0.000 title claims 6
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title claims 6
- 208000020629 overactive bladder Diseases 0.000 title claims 6
- 150000003839 salts Chemical class 0.000 claims 16
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 claims 9
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 8
- 206010027566 Micturition urgency Diseases 0.000 claims 5
- 206010046543 Urinary incontinence Diseases 0.000 claims 5
- RXZMMZZRUPYENV-VROPFNGYSA-N Solifenacin succinate Chemical group OC(=O)CCC(O)=O.C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 RXZMMZZRUPYENV-VROPFNGYSA-N 0.000 claims 3
- -1 2-hydroxy-2-phenylethyl Chemical group 0.000 claims 2
- 206010036018 Pollakiuria Diseases 0.000 claims 2
- 229960001413 acetanilide Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FZERHIULMFGESH-UHFFFAOYSA-N methylenecarboxanilide Natural products CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (13)
1. Farmaceutski sastav, naznačen time, da kao djelotvorne sastojke uključuje (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilid ili njegovu farmaceutski prihvatljivu sol i (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat ili njegovu farmaceutski prihvatljivu sol.
2. Farmaceutski sastav prema zahtjevu 1, naznačen time, da (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilid ili njegova farmaceutski prihvatljiva sol je (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilid.
3. Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat ili njegova farmaceutski prihvatljiva sol je (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat sukcinat.
4. Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 3, naznačen time, da nadalje uključuje farmaceutski prihvatljivo pomoćno sredstvo.
5. Farmaceutski sastav prema zahtjevu 1, naznačen time, da kao djelotvorne sastojke uključuje (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilid ili njegovu farmaceutski prihvatljivu sol u količini od 10 do 100 mg u obliku (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilida, te (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat ili njegovu farmaceutski prihvatljivu sol u količini od 0,5 mg do 10 mg u obliku (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat sukcinata.
6. Farmaceutski sastav prema zahtjevu 5, naznačen time, da uključuje 10 mg do 100 mg od (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilida, i 0,5 mg do 10 mg od (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat sukcinata.
7. Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je to pripravak za oralno davanje.
8. Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se upotrebljava u postupku za liječenje urinarne urgencije, polakisurije i/ili urinarne inkontinencije koje su povezane s hiperaktivnim mjehurom.
9. Uporaba (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilata ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju terapeutskog sredstva koji se upotrebljava u kombinaciji s (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilidom ili njegovom farmaceutski prihvatljivom soli, a koji služi za liječenje urinarne urgencije, polakisurije i/ili urinarne inkontinencije koje su povezane s hiperaktivnim mjehurom.
10. Uporaba (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilida ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju terapeutskog sredstva koji se upotrebljava u kombinaciji s (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilatom ili njegovom farmaceutski prihvatljivom soli, a koji služi za liječenje urinarne urgencije, polakisurije i/ili urinarne inkontinencije koje su povezane s hiperaktivnim mjehurom.
11. (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilid ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u kombinaciji s (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilatom ili njegovom farmaceutski prihvatljivom soli, a služi za uporabu u postupku liječenja urinarne urgencije, polakisurije i/ili urinarne inkontinencije koje su povezane s hiperaktivnim mjehurom.
12. (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u kombinaciji s (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilidom ili njegovom farmaceutski prihvatljivom soli, a služi za uporabu u postupku liječenja urinarne urgencije, polakisurije i/ili urinarne inkontinencije koje su povezane s hiperaktivnim mjehurom.
13. Kombinacija za upotrebu prema zahtjevu 11 ili 12, naznačena time, da se (R)-2-(2-aminotiazol-4-il)-4’-{2-[(2-hidroksi-2-feniletil)amino]etil}acetanilid ili njegova farmaceutski prihvatljiva sol i (3R)-kinuklidin-3-il(1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat ili njegova farmaceutski prihvatljiva sol, primjenuju istovremeno, odvojeno ili uzastopno, ili u odabranim vremenskim intervalima.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007285802 | 2007-11-02 | ||
| PCT/JP2008/069736 WO2009057685A1 (ja) | 2007-11-02 | 2008-10-30 | 過活動膀胱治療用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121078T1 true HRP20121078T1 (hr) | 2013-01-31 |
Family
ID=40591069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121078AT HRP20121078T1 (hr) | 2007-11-02 | 2012-12-28 | Farmaceutski sastav za lijeäśenje hiperaktivnog mjehura |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100240697A1 (hr) |
| EP (1) | EP2216021B1 (hr) |
| JP (1) | JP5263170B2 (hr) |
| CA (1) | CA2704298C (hr) |
| CY (1) | CY1113670T1 (hr) |
| DK (1) | DK2216021T3 (hr) |
| ES (1) | ES2393525T3 (hr) |
| HR (1) | HRP20121078T1 (hr) |
| PL (1) | PL2216021T3 (hr) |
| PT (1) | PT2216021E (hr) |
| SI (1) | SI2216021T1 (hr) |
| WO (1) | WO2009057685A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807135C (en) * | 2010-08-03 | 2019-05-14 | Altherx, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US20150306090A1 (en) * | 2012-08-31 | 2015-10-29 | Astellas Pharma Inc. | Orally administered medical composition |
| ES2750751T3 (es) * | 2014-09-09 | 2020-03-27 | Astellas Pharma Inc | Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria |
| KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
| US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| WO2017186598A1 (en) | 2016-04-25 | 2017-11-02 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| EP3448367A1 (en) | 2016-04-25 | 2019-03-06 | Synthon BV | Tablets comprising mirabegron and solifenacin |
| US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| WO2022006336A1 (en) * | 2020-07-01 | 2022-01-06 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
| EP4159199A1 (en) | 2021-09-29 | 2023-04-05 | Lotus Pharmaceutical Co., Ltd. | Combined formulation of mirabegron and solifenacin |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| DE69823858T2 (de) | 1997-10-17 | 2005-04-28 | Yamanouchi Pharmaceutical Co., Ltd. | Amidderivate oder deren salze |
| US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| JP4466370B2 (ja) * | 2002-06-07 | 2010-05-26 | アステラス製薬株式会社 | 過活動膀胱治療剤 |
| DE60336334D1 (de) | 2002-11-07 | 2011-04-21 | Astellas Pharma Inc | Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff |
| EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| ES2290741T3 (es) * | 2003-04-04 | 2008-02-16 | Dynogen Pharmaceuticals Inc. | Metodo de tratamiento de trastornos del tracto urinario inferior. |
| EP1682183A2 (de) * | 2003-11-03 | 2006-07-26 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
| EP1726304A4 (en) | 2004-03-16 | 2010-04-28 | Astellas Pharma Inc | COMPOSITION CONTAINING SOLIFENACIN |
| US20090131469A1 (en) * | 2005-02-25 | 2009-05-21 | Astellas Pharma Inc. | Pharmaceutical agent comprising solifenacin |
| EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
-
2008
- 2008-10-30 PL PL08843784T patent/PL2216021T3/pl unknown
- 2008-10-30 PT PT08843784T patent/PT2216021E/pt unknown
- 2008-10-30 US US12/740,699 patent/US20100240697A1/en not_active Abandoned
- 2008-10-30 CA CA2704298A patent/CA2704298C/en active Active
- 2008-10-30 SI SI200830841T patent/SI2216021T1/sl unknown
- 2008-10-30 DK DK08843784.3T patent/DK2216021T3/da active
- 2008-10-30 ES ES08843784T patent/ES2393525T3/es active Active
- 2008-10-30 EP EP08843784A patent/EP2216021B1/en not_active Revoked
- 2008-10-30 JP JP2009539100A patent/JP5263170B2/ja active Active
- 2008-10-30 WO PCT/JP2008/069736 patent/WO2009057685A1/ja active Application Filing
-
2012
- 2012-12-28 HR HRP20121078AT patent/HRP20121078T1/hr unknown
-
2013
- 2013-01-04 CY CY20131100004T patent/CY1113670T1/el unknown
- 2013-01-24 US US13/748,956 patent/US8772315B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2216021A4 (en) | 2010-11-03 |
| CA2704298C (en) | 2015-07-21 |
| PL2216021T3 (pl) | 2013-03-29 |
| JP5263170B2 (ja) | 2013-08-14 |
| ES2393525T3 (es) | 2012-12-26 |
| US8772315B2 (en) | 2014-07-08 |
| CY1113670T1 (el) | 2016-06-22 |
| JPWO2009057685A1 (ja) | 2011-03-10 |
| DK2216021T3 (da) | 2012-11-05 |
| CA2704298A1 (en) | 2009-05-07 |
| SI2216021T1 (sl) | 2013-01-31 |
| PT2216021E (pt) | 2012-11-06 |
| EP2216021B1 (en) | 2012-10-17 |
| WO2009057685A1 (ja) | 2009-05-07 |
| EP2216021A1 (en) | 2010-08-11 |
| US20100240697A1 (en) | 2010-09-23 |
| US20130150402A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121078T1 (hr) | Farmaceutski sastav za lijeäśenje hiperaktivnog mjehura | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2009541443A5 (hr) | ||
| SI2529622T1 (en) | Bruton tyrosine kinase inhibitors | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| RU2015117267A (ru) | Замещенные соединения амида | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| TW200606164A (en) | New compounds | |
| BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use |